Zheng et al. demonstrated the efficacy of reducing glycolysis by selectively binding and inhibiting HK2 using the novel compound Benitrobenrazide (BNBZ) in tumor growth xenograft models [336]. This evidence concerns the gene HK2 and neoplasm.